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SUMMARY KEYWORDS
We examined the effect of the acetyl-
cholinesterase (ACHE) inhibitor, donepezil
hydrocloride (DONP), on group II metabo-
tropic glutamate (mGlu) receptor agonist- or
antagonist-induced amnesia in the step-through
passive avoidance task in male mice. DCG-IV, a
group II mGlu receptor agonist, at dose of 50
ng and LY341495, a group II mGlu receptor
antagonist, at dose of 300 ng, significantly
attenuated the latency on the step-through task.
The subcutaneous injection ofDONP at dose of
1 mg/kg 1 hour before passive avoidance
performance ameliorated the amnesia induced
by DCG-IV and LY341495, whereas donepezil
alone did not affect task latency. The results
suggest that activation of group II mGlu
receptors and disinhibition of the cAMP/PKA
signaling pathway (caused by group II mGlu
receptor antagonist) have a negative action on
step-through passive avoidance memory
performance, and that group II mGlu receptors
and ACh interact to modulate learning and
memory function.
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INTRODUCTION
Widely accepted is that the glutamatergic and
cholinergic systems are actively involved in the
processes of learning and memory. In fact, Li et al.
(1997) demonstrated that the NMDA antagonists
MK-801 and CGS-19755 significantly augmented
scopolamine-induced impairment of memory
performance. In addition, Pavlovsky et al. (2003)
revealed that the AChE inhibitor pyridostigmine
enhanced glutamatergic transmission in hippo-
campal CA1 neurons.
Previous behavioral studies on metabotropic
glutamate receptors by Bianchin and coworkers
(1994) showed that ACPD (( S,3R)- 1-aminocyclo-
pentane-l,3-dicarboxylic acid), a selective agonist
for group II mGluRs, enhances memory of the
avoidance task. In addition, Riedel et al. (2002)
suggested that group II mGluRs modulate neural
networks involved in conditioning formation.
Although these recent studies have described a
relation between group II mGluRs and learning
and memory, further studies are necessary to
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define more clearly the nature of this relation. In
previous studies, we suggested that cAMP/protein
kinase A (PKA) signaling-pathway modulation
through group II mGlu receptors coupled with Gi
protein disrupted learning and memory performance
in step-through passive avoidance (Sato et al.,
2003). The relation between ACh and group II
mGlu receptors has been studied by electro-
physiologic methods (Pisani, et al., 2002), but
behavioral studies involving learning and memory
performance have not yet been conducted.
Therefore, the present study was designed to
clarify whether mGlu2/3 receptor agonist- or
antagonist-induced amnesia in a step-through
passive avoidance task would be ameliorated by
the AChE inhibitor, donepezil.
EXPERIMENTAL
Male ddY mice (Kyudou, Ltd., Kumamoto,
Japan), 5 to 6 wk old, were housed with free
access to standard food (Clea Japan Inc.) and
water in an air-conditioned room at a temperature
of24 + C, 50 + 10% humidity, and a constant 12-h
light/dark cycle (lights on between 7:00 and 19:00).
Behavioral experiments were carried out between
9:00 and 17:00. All procedures were approved by
the Committee of Animal Experimentation, Dental
School, Kagoshima University.
The following drugs were used throughout the
experiments: (2S,2’R,3’R)-2-(2’,3 ’-dicarboxyclo-
propyl)glycine (DCG-IV) and (2S)-2-amino-2-
[(1S,2S)-2-carboxy cycloprop-1-yl]-3-(xanth-9-yl)
propanoic acid (LY341495) were purchased from
Tocris Cookson Ltd. (Bristol, UK). Donepezil
hydrochloride (DONP) was obtained from Nippon
Chemiphar Co. Ltd. (Saitama, Japan). LY341495
was dissolved in dimethylsulfoxide (DMSO) and
then diluted with saline to a final concentration of
0.05% (v/v) DMSO. DCG-IV was dissolved in
0.9% saline and the solution was prepared at the
same final DMSO concentration. A DMSO (0.05%)
vehicle was used in control mice. The vehicle,
DCG-IV (50 ng/mouse) or LY341495 (300 ng/
mouse) was intracisternally injected according to
the method of Ueda et al. (1979). The injections
(10 tl each) were completed 10 minutes before the
acquisition trial, according to the method of
Matuoka et al. (1995). DONP was dissolved in
0.9% saline and injected (0.1-1 mg/kg)sub-
cutaneously 60 minutes before the acquisition trial.
Learning and memory ability was assessed by
the step-through-type passive avoidance test using
methods modified from Matuoka et al. (1995). In
short, a two-compartment step-through-type passive
avoidance apparatus was used. The box was divided
into bright (9 9 x 36 cm) and dark compartments
(26 26 x 36 cm) by a guillotine door. In each trial,
a mouse was placed in the illuminated compartment
for a 30-sec habituation period, and then a guillotine
door was raised to allow entry into the dark
chamber. On the pre-exposure session (data not
shown), the step-through latency (the length of time
spent in the bright compartment after a habituation
period) was measured. Mice that stepped through to
the grids of the dark compartment were allowed to
remain there for 30 sec without electrical stimula-
tion and were then returned to their home cage.
After the measurement of the pre-exposure latency,
the acquisition trial was conducted, 10 min after
intracistemal drug injection. When the hind legs of
the mice entered into the dark chamber, the
guillotine door was closed and electrical foot shock
(20 V, duration 80 ms, alternating current) was
delivered through the grid floor for a total of 3 sec.
The time that elapsed before entry into the dark
compartment (latency) was recorded. Retention trials
were then performed at 24 h after the acquisition
trial and the latency was measured for up to 300 sec.
Statistical analysis was performed by one-way
analysis of variance (ANOVA) with the Bonferroni/
Dunn post-hoc test. Statistically significant diff-
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RESULTS AND DISCUSSION
The effects of several doses of DONP, 50 ng
DCG-IV (an mGlu 2/3 receptor agonist), and 300 ng
LY341495 (an mGlu 2/3 receptor antagonist) on each
trail of the step-through performance task are shown
in Fig. 1. One-way ANOVA revealed a significant
diffirence among the six treatment groups on the
retention trial (F(5, 39) 13.50, p < 0.01).
Additionally, post hoc tests showed that the
intracistemal injection of DCG-IV (p < 0.01) or
LY341495 (p < 0.01) significantly suppressed the
latency of the task compared with that of the
vehicle group on the retention trial but not that of
the acquisition trial. In addition, no significant
difference was found between the DONP and
vehicle groups in either trail.
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Fig. 1: Effects ofDONP, DCG-IV and LY341495 on memory performance in the step-through passive avoidance task
in mice. All doses ofDONP were subcutaneously administered hbefore and either vehicle, DCG-IV, or
LY341495 were injected intracisternally 10 min before the acquisition trial. Values are mean + SEM for 7 to 10
animals per group. **p < 0.01 vs. vehicle (one-way ANOVA followed by post-hoc test) on the retention trial.
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As shown in Fig. 2, in the passive avoidance
task DONP significantly affected (A) DCG-IV-
(F[3, 24] 3.29, p < 0.05) and (B) LY341495-
induced (F[3, 24] 3.06, p < 0.05) amnesia on the
retention trial. Post hoc tests showed that DONP at
mg/kg significantly inhibited the amnesia
induced by DCG-IV at 50 ng (A) and by
LY341495 at 300 ng (B) on the retention trial (p <
0.05, for both). No significant differences in
locomotor activity were seen among the treatment
groups (data not shown).
In present study, we found that DONP
administration at mg/kg improved either DCG-IV-
or LY341495-induced impairment of passive-
avoidance performance in mice. The ameliorative
effect of DONP was not caused by non-cognitive
effects, such as a decrease in locomotion or
electrical sensitivity, because the administration
DONP affected neither the locomotor activity nor
the latency of the vehicle group on the acquisition
trial. As mGlu2 and/or mGlu3 receptors are
reportedly linked to the cAMP/PKA signaling
pathway (Schoepp et al., 2001; Robbe et al., 2002),
the inhibition of latency induced by DCG-IV can be
caused by an inhibition of the cAMP/ PKA
signaling pathway via the activation of mGlu2/3
receptors (Schoepp, et al., 2001; Sato, et al., 2003).
The enhancement of glutamate release is known to
be caused by ACh in hippocampal regions, such as
CA1 (Pavlovsky, et al., 2003; Takeda, et al., 2003)
or in the dentate gyrus (Wheal, et al., 1980). The
administration ofDONP at mg/kg might cause an
increase of ACh at synapses, and consequently, the
enhancement of glutamate release could counteract
the inhibition of the cAMP/PKA signaling pathway
induced by DCG-1V via other receptors such as
mGlu and 5, or NMDA receptors. In addition,
DCG-IV reportedly reduces ACh release in the
striatum of rats (Pisani, et al., 2002); therefore, the
administration of DCG-1V at 50 ng might have also
inhibited ACh release in the present study.
Together, these findings suggest that the amelior-
ating effect of donepezil against DCG-IV-induced
amnesia is due to an increase in synaptic ACh.
The administration of LY341495 at 300 ng
reduced the latency on the passive avoidance task,
in agreement with the results in our previous
report (Sato, et al., 2003), therefore reinforcing the
notion that excessive activation of the
cAMP/PKA-signaling pathway impairs learning
and memory. Because LY341495 is an antagonist
of mGlu2 and/or mGlu3 receptors, some think that
LY341495 tends to stimulate cAMP formation
(Kingston et al., 1998). In fact, our previous study
also showed that excessive administration of
forskolin or rolipram decreases latency on the
passive avoidance task (Sato et al., 2003).
Donepezil, however, inhibited the reduction of
latency induced by LY341495.
The mechanism underlying the ameliorating
effect of donepezil is unknown, though we can
speculate on some of the possible mechanisms.
First, donepezil has been reported to increase the
amount ofACh by inhibiting ACHE, thus resulting
in increased levels of ACh, which can bind not
only with postsynaptic muscarinic M1 receptors
but also with presynaptic muscarinic M2 receptors.
Therefore, ACh binding to M2 receptors can
inhibit ACh release through inhibitory feedback.
Consequently, at certain concentrations (achieved
by the inhibitory feedback effect on synaptic ACh
release), ACh decreases the release of glutamate in
the synaptic region (Marchi et al., 1989). Thus, the
decreased glutamate release can ameliorate the
excess (LY341495 induced) activation of the
signaling-pathway. The ameliorating effect of
donepezil might therefore be mediated by the
balance between M1 receptor activation and M2
receptor binding. Also possible is that muscarinic
receptor activation induced by donepezil increases
GABA release in intermediate synapses (Vogt &
Pegehr, 2001), and the released GABA might
modulate the activation of postsynaptic neurons
because this neurotransmitter inhibits a higherDONEPEZIL ABATES MGLU2/3R RELATED DRUGS-CAUSED AMNESIA 323
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Fig. 2: Effects of DONP on the passive avoidance task in mice with DCG-IV- (A) and LY341495- (B) induced
amnesia. All doses of DONP were subcutaneously administered h before the acquisition trial, and DCG-IV
and LY341495 were injected intracisternally 10 min prior to the acquisition trial. Values are mean + SEM for
seven animals per groups. *p < 0.05 vs. DCG-IV; #p < 0.05 vs. LY341495 (one-way ANOVA followed by
post-hoc test) on the retention trial.324 T. SATO ET AL.
dimension function. As mentioned above,
LY341495 can increase glutamate release by
disinhibiting mGlu 2/3 receptors, and the increase
in glutamate release can cause an excess activation
of the cAMP/PKA signaling pathway and an
impairment of learning and memory performance
(Sato et al., 2003). Therefore, the GABA release
induced by donepezil might inhibit the excess
activation of the signaling pathway and restore
optimal activity of the neurons.
Another possibility is that the ameliorating
effect of donepezil might be caused by nicotinic
acetylcholine receptors (nACh-R). Excess glutamate
release resulting from disinhibition by mGlu 2/3
receptor antagonist can cause neuronal cell
damage. In fact, Takeda et al. (2003) reported a
protective effect of donepezil against glutamate
neurotoxicity in rat cortical neurons, which is
consistent with the results of the present study.
Another possibility is that the increase in ACh at
presynaptic nerve terminals modulates glutamate
release via nACh-R, as Santos et al. (2002)
reported that strong and tonic activation of nACh-
R in glutamatergic fibers reduces glutamate release
in pyramidal neurons. Therefore, in the present
study, the reduction of glutamate release might
ameliorate the excess signaling pathway activity
induced by LY341495. A final possibility is that
both the cholinergic and group II mGluR drugs act
on different brain systems because the drugs were
not locally infused.
In conclusion, the results presented here
provide primary evidence that the AChE inhibitor
donepezil can ameliorate group II mGlu receptor
agonist- and antagonist-induced disruption of the
step-through task performance and suggest that the
modulation of glutamate release by ACh might
play an important role in this process. Further
detailed studies are needed to examine the role of
acetylcholine in modulating glutamate release and
cognitive function.
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